University of Cagliari
Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study
Atzori, LCo-prime
Member of the Collaboration Group
;
2021-01-01
Abstract
The anti-tumour necrosis factor (TNF)-α adalimumab is the only licenced biologic for moderate-to-severe hidradenitis suppurativa (HS). No predictors of response have been identified so far.
Files in This Item:
| File | Size | Format | |
|---|---|---|---|
| HS windows of opportunity bjd.18983.pdf Solo gestori archivio
Type: versione post-print
Size 1.58 MB
Format Adobe PDF
|
1.58 MB | Adobe PDF | & nbsp; View / Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.